1.1 OUD Assessment, DSM-5-TR Diagnostic Criteria, and Clinical Opiate Withdrawal Scale (COWS)

Diagnostic Frameworks, DSM-5-TR Criteria & Clinical Opiate Withdrawal Scale (COWS)

Opioid Use Disorder (OUD) is a chronic, relapsing neurobiological disease characterized by neurochemical adaptations in reward, motivational, and autonomic brain circuits. For the Advanced Practice Registered Nurse (APRN) specializing in addictions (CARN-AP), expert diagnosis requires rigorous application of DSM-5-TR criteria, differentiation between normal physiological tolerance and compulsive pathology, mastery of objective withdrawal staging, and an understanding of the erratic pharmacokinetics introduced by synthetic lipophilic contaminants such as illicitly manufactured fentanyl.

---

DSM-5-TR Diagnostic Criteria for Opioid Use Disorder

The American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) conceptualizes OUD as a problematic pattern of opioid use leading to clinically significant impairment or distress. Diagnosis requires meeting at least 2 of 11 criteria within a 12-month period.

The 11 criteria span four functional domains:

1. Impaired Control

• Criterion 1 (Larger amounts/duration): Opioids are often taken in larger amounts or over a longer period than was intended.
• Criterion 2 (Unsuccessful cut-down): Persistent desire or unsuccessful efforts to cut down or control opioid use.
• Criterion 3 (Excessive time spent): A great deal of time is spent in activities necessary to obtain the opioid, use the opioid, or recover from its effects.
• Criterion 4 (Craving): Craving, or a strong desire or urge to use opioids.

2. Social Impairment

• Criterion 5 (Role failure): Recurrent opioid use resulting in a failure to fulfill major role obligations at work, school, or home.
• Criterion 6 (Interpersonal problems): Continued opioid use despite having persistent or recurrent social or interpersonal problems caused or exacerbated by the effects of opioids.
• Criterion 7 (Activities abandoned): Important social, occupational, or recreational activities are given up or reduced because of opioid use.

3. Risky Use

• Criterion 8 (Hazardous use): Recurrent opioid use in situations in which it is physically hazardous (e.g., driving while intoxicated, injecting in unsanitary settings).
• Criterion 9 (Physical/psychological harm): Continued opioid use despite knowledge of having a persistent or recurrent physical or psychological problem that is likely to have been caused or exacerbated by the substance.

4. Pharmacological Criteria

• Criterion 10 (Tolerance): A need for markedly increased amounts of opioids to achieve intoxication or desired effect, or a markedly diminished effect with continued use of the same amount of an opioid.
• Criterion 11 (Withdrawal): The characteristic opioid withdrawal syndrome, or opioids (or a closely related substance) are taken to relieve or avoid withdrawal symptoms.

+---------------------------------------------------------------------------------------+
|                                 DSM-5-TR OUD SEVERITY                                 |
+-----------------------------------+---------------------------------------------------+
| Severity Subtype                  | Diagnostic Criteria Count (within 12-month span)  |
+-----------------------------------+---------------------------------------------------+
| Mild                              | 2 to 3 criteria met                               |
| Moderate                          | 4 to 5 criteria met                               |
| Severe                            | 6 or more criteria met                            |
+-----------------------------------+---------------------------------------------------+

The Mandatory Medical Supervision Exception

Critical Clinical Rule: Under DSM-5-TR, Criterion 10 (Tolerance) and Criterion 11 (Withdrawal) are NOT counted toward a diagnosis of Opioid Use Disorder when the patient is taking opioids solely under appropriate medical supervision.

Physiological neuroadaptation (receptor desensitization, beta-arrestin signaling down-regulation, and cellular dependence) is an expected, inevitable biological response to chronic opioid administration. A patient with cancer or chronic non-cancer pain taking extended-release morphine exactly as prescribed by their clinician will exhibit both tolerance and acute withdrawal upon abrupt cessation. However, in the absence of behavioral signs from the Impaired Control, Social Impairment, or Risky Use domains, this patient has zero qualifying criteria and does not have an Opioid Use Disorder.

Remission Specifiers and Course Criteria

When tracking treatment outcomes and diagnostic evolution, APRNs apply precise DSM-5-TR remission specifiers:

• Early Remission: Full criteria for OUD have previously been met, but no criteria have been met for at least 3 months and less than 12 months (with the sole exception that Criterion 4, Craving, may still be present).
• Sustained Remission: Full criteria for OUD have previously been met, but no criteria have been met for 12 months or longer (again, with the sole exception of Craving).
• "On Maintenance Therapy": Applied if the individual is currently taking a prescribed agonist (methadone), partial agonist (buprenorphine), or antagonist (naltrexone) medication and meets no criteria other than tolerance/withdrawal to that prescribed medication.
• "In a Controlled Environment": Applied if the individual is in an environment where access to opioids is restricted (e.g., closely supervised residential treatment center, locked psychiatric hospital, correctional facility).

---

Opioid Intoxication vs. Opioid Withdrawal Toxidromes

Accurate physical assessment requires recognizing the polar neurobiological presentations of opioid intoxication versus withdrawal. Opioids act on central mu-opioid receptors (MOR) linked to inhibitory G-proteins ($G_{i/o}$), which suppress adenylyl cyclase, decrease cyclic AMP (cAMP), open inwardly rectifying potassium channels, and close voltage-gated calcium channels. This inhibits neuronal firing in the locus coeruleus—the primary noradrenergic center in the pons.

During chronic opioid use, homeostatic up-regulation of adenylyl cyclase occurs. When opioids are withheld, displaced, or cleared, the uninhibited locus coeruleus fires catastrophically, producing a massive noradrenergic storm that drives acute withdrawal symptoms.

---

Clinical Opiate Withdrawal Scale (COWS)

The Clinical Opiate Withdrawal Scale (COWS) is an 11-item validated instrument administered by clinicians to quantify the severity of opioid withdrawal. Scoring guides clinical decision-making, symptom-triggered comfort pharmacotherapy, and buprenorphine induction timing.

                 CLINICAL OPIATE WITHDRAWAL SCALE (COWS) SUMMARY
 0 - 4: No / Minimal Withdrawal
 5 - 12: Mild Withdrawal
 13 - 24: Moderate Withdrawal  <-- Standard target for safe buprenorphine induction (>=8-12)
 25 - 36: Moderately Severe Withdrawal
 > 36: Severe Withdrawal

The 11 COWS Assessment Items

1. Resting Heart Rate (measured for 1 full minute):
   • 0 = pulse $\le 80$ bpm
   • 1 = pulse 81-100 bpm
   • 2 = pulse 101-120 bpm
   • 4 = pulse $> 120$ bpm
2. Sweating (over past 1/2 hour not accounted for by room temperature):
   • 0 = no report of chills or flushing
   • 1 = subjective report of chills or flushing
   • 2 = flushed or moist face
   • 3 = beads of sweat on brow or face
   • 4 = sweat streaming off face
3. Restlessness (observed during interview):
   • 0 = able to sit still
   • 1 = reports difficulty sitting still, but is able to do so
   • 3 = frequent shifting or extraneous movements of legs/arms
   • 5 = unable to sit still for more than a few seconds
4. Pupil Size:
   • 0 = pupils pinned or normal size for room light
   • 1 = pupils possibly larger than normal for room light
   • 2 = pupils moderately dilated
   • 5 = pupils so dilated that only the rim of the iris is visible
5. Bone or Joint Aches (if patient was having pain, only additional aches are scored):
   • 0 = not present
   • 1 = mild diffuse discomfort
   • 2 = patient reports severe diffuse aching of joints/muscles
   • 4 = patient is rubbing joints/muscles and is unable to sit still because of discomfort
6. Runny Nose or Tearing (not accounted for by cold symptoms or allergies):
   • 0 = not present
   • 1 = nasal stuffiness or unusually moist eyes
   • 2 = nose running or tearing
   • 4 = nose constantly running or tears streaming down cheeks
7. GI Upset (over last 1/2 hour):
   • 0 = no GI symptoms
   • 1 = stomach cramps
   • 2 = nausea or loose stool
   • 3 = vomiting or diarrhea
   • 5 = multiple episodes of diarrhea or vomiting
8. Tremor (observation of outstretched hands):
   • 0 = no tremor
   • 1 = tremor can be felt, but not observed
   • 2 = slight tremor observable
   • 4 = gross tremor or muscle twitches
9. Yawning (observed during interview):
   • 0 = no yawning
   • 1 = 1 or 2 yawns during interview
   • 2 = 3 or more yawns during interview
   • 4 = yawning several times per minute
10. Anxiety or Irritability:
    • 0 = none
    • 1 = patient reports increasing irritability or anxiousness
    • 2 = patient obviously irritable or anxious
    • 4 = patient so irritable or anxious that participation in the interview is difficult
11. Gooseflesh Skin (piloerection):
    • 0 = skin is smooth
    • 3 = piloerection palpable or hairs standing up on arms
    • 5 = prominent piloerection (cold turkey appearance)

The "Objective vs. Subjective" Trap in Buprenorphine Induction

A critical pitfall on the CARN-AP exam is premature induction triggered by subjective patient complaints. Because buprenorphine has an exceptionally high receptor affinity ($K_i \approx 0.2$ nM) but lower intrinsic activity (partial agonist), administering it while full agonists occupy mu receptors displaces those agonists and precipitates severe withdrawal.

Patients in early withdrawal frequently report severe subjective distress (10/10 cravings, anxiety, internal aches, mild nausea) when their actual autonomic signs are absent. If an APRN calculates a COWS score of 12 composed purely of subjective points (e.g., anxiety = 2, bone aches = 4, GI cramps = 1, restlessness report = 1, subjective chills = 1, subjective nausea = 2, score = 11), administering buprenorphine will precipitate acute withdrawal.

Core Practice Imperative: Induction requires objective autonomic signs verified on physical exam:

• Resting tachycardia (pulse >80-100 bpm)
• Visible pupil dilation (>4 mm in ambient light)
• Evident piloerection (gooseflesh)
• Observable resting tremor on outstretched hands
• Documented rhinorrhea or lacrimation

---

Pharmacokinetics & Withdrawal Chronology Across Opioid Classes

The onset, peak, and duration of withdrawal depend on the elimination half-life and lipophilicity of the specific opioid.

                  OPIOID WITHDRAWAL TIMELINES ACROSS CLASSES

1. Short-Acting Opioids (Heroin, IR Oxycodone, Morphine)
   Last Use |---- 6-12h ----|=========== 24-48h ===========|--------- 5-7 days ---------|
             Onset of signs             Peak Severity                   Resolution

2. Long-Acting Opioids (Methadone)
   Last Use |---------- 36-72h ----------|======= Days 4-6 =======|------ 2-3 weeks ------|
                    Onset of signs             Peak Severity              Resolution

3. Illicit Synthetic Fentanyl (Chronic / Lipophilic Exposure)
   Last Use |---------------- 24-72h ----------------|==== Erratic Clearance ====>|
              Unpredictable delayed emergence        Prolonged tissue depot leaching

Short-Acting vs. Long-Acting Opioids

• Short-acting opioids (heroin, morphine, oxycodone): Withdrawal manifests within 6 to 12 hours post-use, peaks within 24 to 48 hours, and subsides over 5 to 7 days.
• Long-acting opioids (methadone): Due to tissue accumulation and terminal half-life (24-36 hours), withdrawal emergence is delayed to 36 to 72 hours, peaks at 4 to 6 days, and persists for 2 to 3 weeks.

Fentanyl Lipophilicity and Adipose Sequestration Kinetics

Historically, fentanyl was classified as a short-acting synthetic opioid with an elimination half-life of 2 to 4 hours after single acute exposure. However, illicitly manufactured fentanyl (IMF) used chronically displays fundamentally altered pharmacokinetics:

1. Extreme Lipophilicity: Fentanyl is over 50 to 100 times more lipophilic than morphine, with a vast volume of distribution ($V_d = 3-8$ L/kg).
2. Deep Tissue Sequestration: With repeated daily use, high concentrations saturate peripheral lipid stores and skeletal muscle.
3. Protracted Release: Following cessation, fentanyl leaches slowly and erratically from adipose depots back into the bloodstream, extending its terminal elimination half-life to 24 to 72 hours or longer.
4. The Precipitated Withdrawal Dilemma: Patients may test positive for urinary fentanyl metabolites for 2 to 3 weeks post-cessation. Patients frequently exhibit subjective dysphoria or early withdrawal while central mu receptors remain heavily occupied by depot-leached fentanyl. Standard buprenorphine induction at 12 to 24 hours in chronic fentanyl users carries a high risk of precipitated withdrawal, necessitating micro-induction protocols or delayed initiation based on rigorous objective COWS validation.